132例鼻咽癌调强放疗长期生存及晚期损伤分析

doi:10.3760/cma.j.cn113030-20200915-00468

摘要
图/表
参考文献
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的回顾性分析鼻咽癌调强放疗(IMRT)后长期生存及晚期损伤,为鼻咽癌优化治疗提供参考。方法纳入2003—2009年间于四川省肿瘤医院行IMRT的 132例初治鼻咽癌患者,其中Ⅰ、Ⅱ、Ⅲ、ⅣA、ⅣB期分别为3、22、61、43、3例。中位剂量73.37Gy (66~85Gy)分33次;单纯放疗 20例,同期放化疗 112例。采用Kaplan-Meier法计算生存率,log-rank法检验及单因素预后分析,Cox模型多因素预后分析。应用RTOG/EORTC标准评价晚期放射损伤。结果中位随访时间128个月(3~191个月),全组10、15年鼻咽癌局控率分别为86.0%、79.9%,无瘤生存率分别为72.5%、63.2%,总生存(OS)率分别为65.2%、57.1%。全组局部区域复发率12.1%,远处转移率16.7%。共 53例死亡,其中 15例死于局部区域复发、20例死于远处转移、18例死于其他疾病(肺炎、颅内出血、意外等);10、15年非肿瘤相关死亡率分别为11.3%、13.6%。单因素分析示年龄、吸烟史、乳酸脱氢酶、T分期、临床分期是鼻咽癌OS的独立预后因素;多因素分析示乳酸脱氢酶、T分期、同期放化疗是鼻咽癌OS的预后因子。1-2级晚期损伤(听力下降、吞咽困难、龋齿、口干较高)发生率为90.4%,3-4级晚期损伤(皮肤纤维化、听力下降、放射性脑损伤)发生率8.5%。结论鼻咽癌患者IMRT后10、15年OS较好,但随着生存期延长非肿瘤相关死亡率升高;远处转移为治疗失败的主要原因;晚期损伤主要为1-2级听力下降、吞咽困难、龋齿、口干。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	方曾怡
	吴自飞
	吴川
	罗成
	高明权
	赖昕
	罗丽萍
	王卫东
	郎锦义

关键词 ：鼻咽肿瘤/调强放射疗法, 预后, 晚期损伤

Abstract：Objective To retrospectively analyze the long-term survival (10-15 years) and late toxicity of nasopharyngeal carcinoma (NPC) patients after intensity-modulated radiotherapy (IMRT), aiming to provide reference for the optimal treatment of NPC. Methods 132 patients with NPC who were treated with IMRT in Sichuan Cancer Hospital from 2003 to 2009 were recruited. Among them, 3 patients were classified as stage Ⅰ, 22 cases of grade Ⅱ, 61 cases of grade Ⅲ, 43 cases of ⅣA and 3 cases of ⅣB, respectively. The median dose was 73.37Gy (66 to 85Gy), divided into 33 times. Twenty patients received radiotherapy alone, 112 cases of concurrent radiochemotherapy. The survival rate was calculated by Kaplan-Meier method and log-rank test. Univariate prognostic analysis was performed. Cox model was used to conduct multivariate prognostic analysis. The late radiation toxicity was evaluated by RTOG/EORTC criteria. Results The median follow-up duration was 128 months (range, 3 to 191 months). The 10-and 15-year local control rates of NPC patients were 86.0% and 79.9%. The disease-free survival rates were 72.5% and 63.2%, and the overall survival (OS) rates were 65.2% and 57.1%. The local recurrence rate was 12.1%, and the distant metastasis rate was 16.7%. A total of 53 patients died, of whom 15 patients died of local recurrence, 20 patients died of distant metastasis and 18 patients died of other diseases (pneumonia, intracranial hemorrhage and accident, etc.). The 10-and 15-year non-tumor-related mortality rates were 11.3% and 13.6%. Univariate analysis showed that age, smoking habit, lactate dehydrogenase (LDH), T stage and clinical stage were the independent prognostic factors of OS in NPC patients. Multivariate analysis demonstrated that LDH, T stage and synchronous chemotherapy were the prognostic factors of OS in NPC patients. The incidence of gradeⅠ-Ⅱ late radiation injury (hearing impairment, dysphagia, dental caries and xerostomia) was 90.4%,and 8.5% for grade Ⅲ-Ⅳ late radiation injury (skin fibrosis, hearing impairment and radiation brain injury). Conclusions The 10-and 15-year OS of NPC patients treated with IMRT is relatively high. With the prolongation of survival, the non-tumor-related mortality rate is increased. Distant metastasis is the main cause of treatment failure. The main late injuries include grade Ⅰ/Ⅱ hearing impairment, dysphagia, dental caries and xerostomia.

Key words： Nasopharyngeal neoplasm/intensity-modulated radiotherapy Prognosis Late radiation injury

收稿日期: 2020-09-15

基金资助:国家重点研发计划(2017YFC0113904);四川省重点研发专项(2017SZ0004)

通讯作者: 王卫东,Email:wwdwyl@sina.com;郞锦义,Email:Langjy610@163.com

引用本文:

方曾怡,吴自飞,吴川等. 132例鼻咽癌调强放疗长期生存及晚期损伤分析[J]. 中华放射肿瘤学杂志, 2021, 30(7): 653-658.

Fang Zengyi,Wu Zifei,Wu Chuan et al. Analysis of long-term survival outcomes and late radiation toxicity of 132 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy[J]. Chinese Journal of Radiation Oncology, 2021, 30(7): 653-658.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20200915-00468 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2021/V30/I7/653

[1] 梁锌,杨剑,高婷,等. 中国鼻咽癌流行概况[J]. 中国肿瘤,2016, 5(11):835-840.
Liang X, Yang J, Gao T, et al. Nasopharynx cancer epidemiology in China[J]. China Cancer, 2016, 25(11):835-840.
[2] 蒋朝阳,张涛,高辉,等.406例鼻咽癌患者颈部及Ⅴ区后缘间隙淋巴结转移的预后分析[J]. 中国肿瘤临床,2017,44(20):1019-1023. DOI:10.3969/j.issn.1000-8179.2017.20.631.
Jiang CY, Zhang T, Gao H, el al. Prognosis of cervical and posterior to level V lymph node metastasis in 406 cases of nasopharyngeal carcinoma[J]. Chin J Clin Oncol, 2017,44(20):1019-1023. DOI:10.3969/j.issn.1000-8179.2017.20.631.
[3] 赵充,肖巍魏,韩非,等.419例鼻咽癌患者调强放疗疗效和影响[J]. 中华放射肿瘤学杂志,2010, 19(3):191-196. DOI:10.3760/cma.j.issn.1004-4221.2010.03.005.
Zhao C, Xiao WW, Han F, el al. Long-term outcome and prognostic of patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy[J]. Chin J Radiat Oncol, 2010, 19(3):191-196. DOI:10.3760/cma.j.issn.1004-4221.2010.03.005.
[4] Radiation Therapy Oncology GROUP. A phase Ⅱ study of concurrent chemoradiotherapy using three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT)+ bevacizumab (BV) for locally or regionally advanced nasopharyngeal cancer[DB/OL][2011-03-05].http://rpc.mdanderson.org/rpc/credentialing/files.
[5] Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase Ⅲ comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer[J]. J Clin Oncol, 2003, 21(1):92-98. DOI:10.1200/JCO.2003.01.008.
[6] Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11:a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer[J]. J Clin Oncol, 2013, 31(7):845-852. DOI:10.1200/JCO.2012.43.6097.
[7] Kam MKM, Teo Pml, Chau RMC, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy:the Hong Kong experience[J]. Int J Radiat Oncol Biol Phys, 2004, 60(5):1440-1450. DOI:10.1016/j.ijrobp.2004.05.022.
[8] Peng G, Wang T, Yang KY, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma[J]. Radiother Oncol, 2012, 104(3):286-293. DOI:10.1016/j.radonc.2012.08.013.
[9] Tham IW, Hee SW, Yeo RM, et al. Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the national cancer centre singapore experience[J]. Int J Radiat Oncol Biol Phys, 2009, 75(5):1481-1486. DOI:10.1016/j.ijrobp.2009.01.018.
[10] Fang FM, Chien CY, Tsai WL, et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy-a longitudinal study[J]. Int J Radiat Oncol Biol Phys, 2008, 72(2):356-364. DOI:10.1016/j.ijrobp.2007.12.054.
[11] Lin S, Pan J, Han L, et al. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy:report on the 3-year outcome of a prospective series[J]. Int J Radiat Oncol Biol Phys, 2009, 75(4):1071-1078. DOI:10.1016/j.ijrobp.2008.12.015.
[12] 田允铭,韩非,曾雷,等. 鼻咽癌调强放疗后长期生存结果及失败模式分析[J]. 中华放射肿瘤学杂志, 2018, 27(10):880-885. DOI:10.3760/cma.j.issn.1004-4221.2018.10.002.
Tian YM, Han F, Zeng L, el al. Long-term survival outcome and failure pattern after intensity-modulated radiotherapy for nasopharyngeal carcinoma[J]. Chin J Radiat Oncol, 2018, 27(10):880-885. DOI:10.3760/cma.j.issn.1004-4221.2018.10.002.
[13] Wu LR, Liu Y T, Jiang N, et al. Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy:an analysis of 614 patients from a single center[J]. Oral Oncol, 2017, 69(1):26-32. DOI:10.1016/j.oraloncology.2017.03.015.
[14] Zhang L, Zhao C, Ghimire B, et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population:a meta-analysis of the phase Ⅲ randomized trials[J]. BMC Cancer, 2010, 10(1):558. DOI:10.1186/1471-2407-10-558.
[15] Sun Y, Ma J, Lu TX, et al. Regulation for distribution of metastatic cervical lymph nodes of 512 cases of nasopharyngeal carcinoma[J]. Ai Zheng, 2004, 23(11 suppl):1523-1527.
[16] Wan XB, Wei L, Li H, et al. High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma[J]. Eur J Cancer, 2013, 49(10):2356-2364. DOI:10.1016/j.ejca.2013.03.008.
[17] 刘晓清,罗伟,刘孟忠,等.1093例初治鼻咽癌的疗效和预后分析[J]. 中华放射肿瘤学杂志,2008, 17(2):81-86. DOI:10.3321/j.issn:1004-4221.2008.02.001.
Liu XQ, Luo W, Liu MZ, et al. Treatment results and prognostic analysis of 1093 primary nasopharyngeal carcinoma[J]. Chin J Radiat Oncol, 2008, 17(2):81-86. DOI:10.3321/j.issn:1004-4221.2008.02.001.
[18] 肖光莉,丘熹彬,王卫华,等. 鼻咽癌调强放疗长期疗效及预后分析[J]. 中华放射肿瘤学杂志,2012, 21(6):488-491. DOI:10.3760/cma.j.issn.1004-4221.2012.06.002.
Xiao GL, Qiu XB, Wang WH, et al. Long-term outcome and prognostic factors of nasopharyngeal carcinoma treated by intensity modulated radiotherapy[J]. Chin J Radiat Oncol, 2012, 21(6):488-491. DOI:10.3760/cma.j.issn.1004-4221.2012.06.002.
[19] 尹丽,郭文杰,解鹏,等. 局部复发鼻咽癌超分割IMRT的临床分析[J]. 中华放射肿瘤学杂志,2016, 25(9):917-922. DOI:10.3760/cma.j.issn.1004-4221.2016.09.002.
Yin L, Guo WJ, Xie P, et al. Efficacy of intensity-modulated radiotherapy on patients with locally recurrent nasopharyngeal carcinoma[J]. Chin J Radiat Oncol, 2016, 25(9):917-922. DOI:10.3760/cma.j.issn.1004-4221.2016.09.002.
[20] 孔琳,张有望,吴永如,等. 鼻咽癌放疗后长期生存者晚期副反应研究[J]. 中华放射肿瘤学杂志,2006, 15(3):153-156. DOI:10.3760/j.issn:1004-4221.2006.03.001.
Kong L, Zhang YW, Wu YR, et al. Late side reactions of long-term survivors after radiotherapy for nasopharyngeal carcinoma[J]. Chin J Radiat Oncol, 2006, 15(3):153-156. DOI:10.3760/j.issn:1004-4221.2006.03.001.

[1]	宣亮, 赵旭冉, 孙慧茹, 尹珺, 唐玉, 景灏, 房辉, 宋永文, 金晶, 刘跃平, 任骅, 陈波, 亓姝楠, 李宁, 唐源, 卢宁宁, 杨勇, 吴世凯, 李晔雄, 王淑莲, 孙冰. 乳腺癌根治术后单纯胸壁复发放疗和胸壁再复发的预后分析[J]. 中华放射肿瘤学杂志, 2021, 30(9): 898-902.